Sunday, April 30, 2017 6:30:33 AM
"About 150 million dollar market cap so we have cash for a number of years so we're in very good shape here."
Thanks for compiling these. I liked the minimum of editorial comment because they generally speak best for themselves, but in case anyone missed your point on this one here it is:
A company's market cap has ABSOLUTELY NOTHING to do with its cash position (it's simply the outstanding share count times the share price) so for him to say that the size of NNVC's market cap indicates that it has cash for a number of years is a non sequitur....in other words it's unrelated bullshit.
ps. The market cap on the date published was actually a bit more than $170M....a week prior to publication it had been about $150M (so he was right about something). Today it's about $80M. The company had about $25M in Cash at the time of the interview and it had about $19M as of 12/31/16.
The cash position has slipped and market cap has shrunk and they may be marginally related (the market doesn't totally ignore cash position), but market cap STILL isn't a measure of cash position as Seymour would have his listeners believe it is. It's impossible to tell if he was being intentionally deceptive or if he just didn't know something that EVERY public company CEO should know. He does have a bit of a history on that score, though.
I was given that information....I don't know.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM